Relay Therapeutics, Inc. RLAY Proceeds From Issuance Of Common Stock Via At The Market Offerings Net
Proceeds From Issuance Of Common Stock Via At The Market Offerings Net at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlay:ProceedsFromIssuanceOfCommonStockViaAtTheMarketOfferingsNet.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s proceeds from issuance of common stock via at the market offerings net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s proceeds from issuance of common stock via at the market offerings net?
- Relay Therapeutics, Inc. (RLAY) reported proceeds from issuance of common stock via at the market offerings net of $137.09M in Q1 2026.
- What does proceeds from issuance of common stock via at the market offerings net mean?
- Measures the cash proceeds received from selling common stock directly into the public market at prevailing market prices over time. This financing mechanism provides the company with flexibility to raise capital incrementally without the need for a formal underwritten offering. It highlights the company's reliance on public equity markets for ongoing liquidity needs.